NEOG · Neogen Corporation · Stock research

Current Thesis

The narrative leg on offer is a post-merger cleanup finally showing up in the numbers. Neogen spent three years digesting the 3M Food Safety business; on 2026-07-30 it reported Q4 FY26 revenue of $225.3M against $212.355M consensus and adjusted EPS of $0.09 against a $(0.07) consensus, guided FY27 revenue to $880–885M versus $849.644M consensus, and paired that with a $160M sale of its Genomics unit to Zoetis whose ~$140M of net proceeds are earmarked primarily for debt reduction. Shares gapped roughly 10% on the print and closed 2026-08-07 at $11.47, 4.7% under the $12.04 52-week high.

Life-cycle placement: ACCELERATING, dated to 2026-07-30 (first genuine beat-and-raise of the post-integration period, ~10% single-session move) and 2026-08-03 (Piper Sandler lifted its target to $13 from $11). The label is fragile rather than entrenched: the re-rating is one quarter old and the stock is already trading inside the published target range. If September passes with the stock grinding under $12.04 and no estimate revisions above the current $13 high target, the honest label becomes MATURING.

Bullish and bearish views on Neogen Corporation

The model's bull view on Neogen Corporation (NEOG), in brief: Q4 FY26 beat both lines (2026-07-30): revenue $225.3M vs $212.355M consensus; adjusted EPS $0.09 vs $(0.07) consensus. The bear view: The growth rate is still low-single-digit. Both cases follow in full.

Bull Case

• Q4 FY26 beat both lines (2026-07-30): revenue $225.3M vs $212.355M consensus; adjusted EPS $0.09 vs $(0.07) consensus. Adjusted EBITDA $45.4M at a 20.2% margin, +12% YoY.
• Food Safety inflected: segment revenue $166.8M on 5.8% core growth, the strongest in three years, with bacteria and general sanitation +10% and indicator testing/culture media +9% (Q4 FY26 presentation, 2026-07-30).
• FY27 guide above the Street on both metrics: revenue $880–885M vs $849.644M consensus; adjusted EBITDA $180–182M against FY26's $177.8M. Q1 FY27 guided to $207–209M vs $204.710M consensus with adjusted EBITDA of roughly $37M.
• Deleveraging path is specified, not implied: gross debt $794M and cash $186M at 2026-05-31, net debt $608M. Management targets leverage below 3x by the end of calendar 2026, funded partly by ~$140M net proceeds from the Genomics sale, which it expects to complete by the end of FY27's first half.
• Cash conversion turned: Q4 operating cash flow exceeded $30M and free cash flow was $26M, the highest quarterly level of FY26.
• A named margin lever with a number attached: the Petrifilm manufacturing transition is targeted at 200–300bps of gross margin expansion, against $25M allocated to FY27 transformation initiatives.
• Sell-side is moving up without being enthusiastic: Piper Sandler raised its target to $13 from $11 on 2026-08-03 while keeping a Neutral rating — the estimate cut cycle appears to have stopped.

Bear Case

• The growth rate is still low-single-digit. FY26 revenue was $870.4M on 1.9% core growth; the FY27 midpoint of $882.5M implies roughly 3% core. The equity case rests on margin and balance-sheet repair, not on demand acceleration.
• Reconciliation gap worth checking: how the mid-year Genomics divestiture is treated inside the $880–885M FY27 range against the $870.4M FY26 base is not something this note can resolve from the headline release, and it changes the underlying organic comparison.
• Regulatory hold on the funding source. The ACCC issued a Phase 2 notice on 2026-07-17, finding the transaction would combine "the two largest suppliers of genomic testing services for cattle in Australia," and separately flagged Zoetis' access to cattle and sheep genetic data. Submissions closed 2026-07-31. Phase 2 runs up to 90 business days from the notice and no determination date has been published.
• Animal Safety is barely positive: +0.5% core growth in Q4 FY26 after supply issues, one quarter off the bottom.
• Leverage is real: $608M net debt against $177.8M of FY26 adjusted EBITDA. The sub-3x path assumes both the sale closing and EBITDA holding at guide.
• Valuation sits inside the published range: the 2026-08-07 close of $11.47 compares with a $12.00 median and $13.00 high across the seven analysts tracked by stockanalysis.com. Follow-through from here requires new estimates, not the re-rating of existing ones.

Setup & Price Structure

• Basis: 2026-08-07 close $11.47; 52-week high $12.04 (−4.7%); three-month return +26.7%; RSI(14) 65.9.
• The advance is print-driven. The ~10% move on 2026-07-30 created the shelf the entire structure now rests on; there has been no meaningful retest of it in the sessions since.
• $12.04 is the level a new leg has to clear. Below it, the untested question is whether the post-print consolidation holds or whether the gap fills back toward the pre-announcement range.
• Crowding and positioning observables (stated, not judged): RSI(14) at 65.9 with price 4.7% off the high after a 26.7% three-month run; a price-target raise on 2026-08-03 that did not carry a rating change; a close beneath the $12.00 consensus median but above the $10.00 low target; no earnings date inside 30 days (the prior-year Q1 was released 2025-10-09); and no Form 4 or registration-statement activity in the 30-day filing record reviewed for this note.

Catalyst Calendar (next 30 days)

• 2026-08-08 → 2026-09-07: no confirmed company-specific event. The window between the FY26 report and the Q1 FY27 print is empty of scheduled disclosure, which leaves the tape dependent on regulatory headlines and sector flow.
• ~2026-10-08 (est.): Q1 FY27 results. Prior-year Q1 was released 2025-10-09. The bar is management's own $207–209M revenue and ~$37M adjusted EBITDA.
• By 2026-11-30 (end of FY27 first half): management's stated completion window for the $160M Genomics transaction.
• By 2026-12-31: management's stated timing for leverage below 3x.

Elapsed catalysts

• Open, notice dated 2026-07-17, statutory window up to 90 business days: ACCC Phase 2 determination on Zoetis/Neogen Genomics. No decision date published. (passed 23d ago)

What Would Change Our Mind

The weak point is sample size. FY26 core growth was 1.9%; Q4's 4.3% and Food Safety's 5.8% are one observation each. A Q1 FY27 print at or below the $207M low end of guidance, or Food Safety core growth back under 3%, would reframe the June-quarter acceleration as timing rather than demand.

The second break is regulatory. The deleveraging leg is funded by a transaction an Australian regulator has already flagged as potentially substantially lessening competition. An ACCC determination that blocks the deal or imposes a structural remedy would put both the ~$140M of net proceeds and the sub-3x-by-year-end leverage target in question; the observable would be management dropping or qualifying that leverage language at the Q1 FY27 call.

On price, a weekly close below $10.00 surrenders the post-2026-07-30 advance and returns the stock to the range it occupied before the print — at which point the beat-and-raise has been rejected by the market that received it. A softer related signal: the stock spending September under $12.04 with no target revisions above $13 would move the narrative from ACCELERATING to MATURING and thin out the incremental bid.

Correlation Notes

• Zoetis (ZTS) is a direct counterparty. Headlines on the ACCC review move Neogen's balance-sheet arithmetic far more than Zoetis' — the asymmetry runs one way given the relative size of the $160M consideration to each company.
• Comparables cluster in food/pharma QC and life-science tools: Bio-Rad, Thermo Fisher, Mettler-Toledo and Qiagen on the consumables and instrument side; IDEXX on animal diagnostics. The Petrifilm franchise came from 3M's Food Safety business, so 3M's consumables manufacturing history is the reference point for transition execution risk.
• Protein and cattle-herd cycle: Animal Safety and genomics testing volumes track cattle and poultry throughput, an exposure largely uncorrelated with the diagnostics multiple itself.
• Credit sensitivity: with $794M gross debt against $186M cash at 2026-05-31, the equity is a levered claim. High-yield spread widening compresses the multiple independently of operating results until the paydown lands.
• Not an AI-adjacent name. Neogen does not move with semiconductor or data-center flow, which makes its drawdowns idiosyncratic and its rallies dependent on company-specific disclosure rather than theme rotation.